NASDAQ:LPTX Leap Therapeutics (LPTX) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free LPTX Stock Alerts $3.25 -0.04 (-1.22%) (As of 11:40 AM ET) Add Compare Share Share Today's Range$3.11▼$3.2950-Day Range$2.14▼$3.4152-Week Range$1.24▼$10.20Volume82,068 shsAverage Volume313,957 shsMarket Capitalization$83.20 millionP/E RatioN/ADividend YieldN/APrice Target$11.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Leap Therapeutics alerts: Email Address Leap Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside252.2% Upside$11.38 Price TargetShort InterestBearish4.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.08) to ($1.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.09 out of 5 starsMedical Sector767th out of 907 stocksPharmaceutical Preparations Industry360th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingLeap Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLeap Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.87% of the float of Leap Therapeutics has been sold short.Short Interest Ratio / Days to CoverLeap Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Leap Therapeutics has recently increased by 0.88%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLeap Therapeutics does not currently pay a dividend.Dividend GrowthLeap Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LPTX. Previous Next 0.6 News and Social Media Coverage Search Interest14 people have searched for LPTX on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Leap Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Leap Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.30% of the stock of Leap Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.46% of the stock of Leap Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Leap Therapeutics are expected to grow in the coming year, from ($2.08) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Leap Therapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Leap Therapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLeap Therapeutics has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsWall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.Click here for the stock details About Leap Therapeutics Stock (NASDAQ:LPTX)Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Read More LPTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LPTX Stock News HeadlinesApril 11, 2024 | markets.businessinsider.comLeap Therapeutics To Sell $40 Mln Of Shares In Private Placement; Stock Up Over 14%April 11, 2024 | prnewswire.comLeap Therapeutics Announces $40 Million Private PlacementApril 25, 2024 | Chaikin Analytics (Ad)Wall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.March 26, 2024 | insidermonkey.com5 Best Biotech Penny Stocks to Invest InMarch 19, 2024 | markets.businessinsider.comLeap Therapeutics: Promising Clinical Outcomes and Upcoming Catalysts Bolster Buy RatingMarch 18, 2024 | investorplace.comLPTX Stock Earnings: Leap Therapeutics Beats EPS for Q4 2023March 18, 2024 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | finance.yahoo.comLeap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 25, 2024 | Chaikin Analytics (Ad)Wall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.March 15, 2024 | finance.yahoo.comLPTX Apr 2024 5.000 callFebruary 17, 2024 | finance.yahoo.comLPTX Mar 2024 7.000 callJanuary 26, 2024 | markets.businessinsider.comOutperform Rating on Leap Therapeutics Amid Promising Gastric Cancer Trial OutcomesJanuary 17, 2024 | msn.comEvolus, Leap Therapeutics among healthcare moversJanuary 16, 2024 | finance.yahoo.comLeap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers SymposiumJanuary 6, 2024 | markets.businessinsider.comOptimism High as Leap Therapeutics’ Studies Suggest Potential for Significant Shareholder ValueJanuary 4, 2024 | ca.finance.yahoo.comLPTX Jun 2024 1.000 callJanuary 4, 2024 | ca.finance.yahoo.comLPTX Mar 2024 1.000 callJanuary 3, 2024 | finance.yahoo.comLeap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2024 | finance.yahoo.comLeap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer PatientsDecember 11, 2023 | finance.yahoo.comLeap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers SymposiumNovember 21, 2023 | finance.yahoo.comLeap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare ConferenceNovember 14, 2023 | markets.businessinsider.comRaymond James Maintains Outperform Rating for Leap Therapeutics: Here's What You Need To KnowNovember 13, 2023 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports Third Quarter 2023 Financial ResultsNovember 13, 2023 | benzinga.comRecap: Leap Therapeutics Q3 EarningsNovember 13, 2023 | finance.yahoo.comLeap Therapeutics Reports Third Quarter 2023 Financial ResultsSeptember 5, 2023 | finance.yahoo.comLeap Therapeutics to Participate at Upcoming Investor ConferencesAugust 15, 2023 | msn.comHC Wainwright & Co. Maintains Leap Therapeutics (LPTX) Buy RecommendationSee More Headlines Receive LPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LPTX CUSIPN/A CIK1509745 Webwww.leaptx.com Phone(617) 714-0360FaxN/AEmployees54Year FoundedN/APrice Target and Rating Average Stock Price Target$11.38 High Stock Price Target$17.50 Low Stock Price Target$7.00 Potential Upside/Downside+245.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($5.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-133.17% Return on Assets-90.90% Debt Debt-to-Equity RatioN/A Current Ratio5.64 Quick Ratio5.64 Sales & Book Value Annual Sales$1.50 million Price / Sales56.15 Cash FlowN/A Price / Cash FlowN/A Book Value$2.35 per share Price / Book1.40Miscellaneous Outstanding Shares25,600,000Free Float22,707,000Market Cap$84.22 million OptionableOptionable Beta0.57 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Douglas E. Onsi J.D. (Age 55)CFO, General Counsel, Treasurer & Secretary, President, CEO & Director Comp: $1.04MMr. Augustine J. Lawlor (Age 67)Chief Operating Officer Comp: $713.57kDr. Cynthia A. Sirard (Age 54)Chief Medical Officer Comp: $708.64kDr. Jason S. Baum Ph.D. (Age 45)Chief Scientific Officer Mr. Mark O'Mahony (Age 53)Chief Manufacturing Officer Ms. Christine M. Granfield (Age 56)VP and Head of Regulatory Affairs & Quality More ExecutivesKey CompetitorsAffimedNASDAQ:AFMDLifeVantageNASDAQ:LFVNChimerixNASDAQ:CMRXQ32 BioNASDAQ:QTTBAileron TherapeuticsNASDAQ:ALRNView All CompetitorsInstitutional OwnershipKey Client Fiduciary Advisors LLCBought 18,408 shares on 4/15/2024Ownership: 0.910%Simplex Trading LLCBought 22,900 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions LPTX Stock Analysis - Frequently Asked Questions Should I buy or sell Leap Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LPTX shares. View LPTX analyst ratings or view top-rated stocks. What is Leap Therapeutics' stock price target for 2024? 4 Wall Street analysts have issued 12-month target prices for Leap Therapeutics' shares. Their LPTX share price targets range from $7.00 to $17.50. On average, they anticipate the company's stock price to reach $11.38 in the next year. This suggests a possible upside of 252.2% from the stock's current price. View analysts price targets for LPTX or view top-rated stocks among Wall Street analysts. How have LPTX shares performed in 2024? Leap Therapeutics' stock was trading at $4.15 on January 1st, 2024. Since then, LPTX shares have decreased by 22.2% and is now trading at $3.23. View the best growth stocks for 2024 here. When is Leap Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our LPTX earnings forecast. How were Leap Therapeutics' earnings last quarter? Leap Therapeutics, Inc. (NASDAQ:LPTX) posted its quarterly earnings results on Monday, March, 18th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.10. What ETF holds Leap Therapeutics' stock? Simplify Health Care ETF holds 529,326 shares of LPTX stock, representing 1.19% of its portfolio. When did Leap Therapeutics' stock split? Shares of Leap Therapeutics reverse split on the morning of Wednesday, June 21st 2023. The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Leap Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Amarin (AMRN), OPKO Health (OPK), VYNE Therapeutics (VYNE), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB) and Rigel Pharmaceuticals (RIGL). Who are Leap Therapeutics' major shareholders? Leap Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Key Client Fiduciary Advisors LLC (0.91%). View institutional ownership trends. How do I buy shares of Leap Therapeutics? Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LPTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
